Sandra A Jablonski
Overview
Explore the profile of Sandra A Jablonski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shuptrine C, Ajina R, Fertig E, Jablonski S, Lyerly H, Hartman Z, et al.
Cancer Immunol Immunother
. 2017 Aug;
66(12):1529-1544.
PMID: 28770278
The clinical successes of immune checkpoint therapies for cancer make it important to identify mechanisms of resistance to anti-tumor immune responses. Numerous resistance mechanisms have been identified employing studies of...
12.
Varghese R, Zuo Y, Zhao Y, Zhang Y, Jablonski S, Pierobon M, et al.
Methods
. 2017 Jun;
124:89-99.
PMID: 28651964
In this paper, we introduce a novel computational method for constructing protein networks based on reverse phase protein array (RPPA) data to identify complex patterns in protein signaling. The method...
13.
Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, et al.
Clin Cancer Res
. 2016 Jul;
22(24):6153-6163.
PMID: 27384421
Purpose: Even when diagnosed prior to metastasis, pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with almost 90% lethality, emphasizing the need for new therapies optimally targeting the tumors of...
14.
Murray J, Aldeghaither D, Wang S, Nasto R, Jablonski S, Tang Y, et al.
Cancer Immunol Res
. 2014 Oct;
2(12):1186-98.
PMID: 25300860
Monoclonal antibodies (mAb) can modulate cancer cell signal transduction and recruit antitumor immune effector mechanisms-including antibody-dependent cellular cytotoxicity (ADCC). Although several clinically effective antibodies can promote ADCC, therapeutic resistance is...
15.
Surana R, Wang S, Xu W, Jablonski S, Weiner L
Cancer Immunol Res
. 2014 Sep;
2(11):1103-12.
PMID: 25204776
Tumor-targeted antibody therapy has had a major impact on reducing morbidity and mortality in a wide range of cancers. Antibodies mediate their antitumor activity in part by activating immune effector...
16.
Astsaturov I, Ratushny V, Sukhanova A, Einarson M, Bagnyukova T, Zhou Y, et al.
Sci Signal
. 2010 Sep;
3(140):ra67.
PMID: 20858866
Intrinsic and acquired cellular resistance factors limit the efficacy of most targeted cancer therapeutics. Synthetic lethal screens in lower eukaryotes suggest that networks of genes closely linked to therapeutic targets...
17.
Pugacheva E, Jablonski S, Hartman T, Henske E, Golemis E
Cell
. 2007 Jul;
129(7):1351-63.
PMID: 17604723
The mammalian cilium protrudes from the apical/lumenal surface of polarized cells and acts as a sensor of environmental cues. Numerous developmental disorders and pathological conditions have been shown to arise...
18.
Rula M, Cai K, Moore R, Yang D, Staub C, Capo-Chichi C, et al.
Genesis
. 2007 May;
45(6):327-38.
PMID: 17506089
The differentiation and formation of the primitive endoderm in early embryos can be mimicked in vitro by the aggregation of embryonic stem cells to form embryoid bodies. We present morphological...
19.
Liu S, Rattner J, Jablonski S, Yen T
J Cell Biol
. 2006 Oct;
175(1):41-53.
PMID: 17030981
We report the interactions amongst 20 proteins that specify their assembly to the centromere-kinetochore complex in human cells. Centromere protein (CENP)-A is at the top of a hierarchy that directs...
20.
Robbins A, Jablonski S, Yen T, Yoda K, Robey R, Bates S, et al.
Cell Cycle
. 2005 Apr;
4(5):717-26.
PMID: 15846093
The kinetochore, a multi-protein complex assembled on centromeric chromatin in mitosis, is essential for sister chromosome segregation. We show here that inhibition of histone deacetylation blocks mitotic progression at prometaphase...